Medilabo RFP has been awarded a ¥260 million (approx. $1.7 million) grant from the Japan Agency for Medical Research and Development (AMED) under its Clinical Research and Trial Promotion Program (Step 1). The funding will support IND-enabling studies for ML1707, an intranasal tau oligomer inhibitor for Alzheimer’s and FTD, and preparation for a Phase 1 IND application in Japan.